← Back to Search

Other

XXB750 for Heart Failure

Phase 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Current symptom(s) of HF NYHA class II-III and LVEF < 50%
Receiving standard of care background HF therapy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 16

Summary

This trial will study the effectiveness, safety, and tolerability of XXB750 in patients with heart failure. It will be conducted at multiple centers and will last for 24 weeks. The trial will

Who is the study for?
This trial is for people with heart failure symptoms classified as NYHA class II-III and a left ventricular ejection fraction (LVEF) less than 50%. Participants must have elevated NT-proBNP levels and be on standard heart failure treatments. It's not specified who can't join.
What is being tested?
The study tests different doses of XXB750 against Sacubitril/valsartan (a known heart failure medication) and a placebo over 24 weeks. Patients are randomly assigned to one of these options at multiple centers.
What are the potential side effects?
While specific side effects aren't listed, common ones for new heart medications may include low blood pressure, kidney problems, high potassium levels, dizziness, or changes in heartbeat.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have heart failure symptoms and my heart's pumping ability is reduced.
Select...
I am on standard heart failure treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 16 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in log NT-proBNP from baseline to Week 16

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Arm 4Experimental Treatment1 Intervention
XXB750 High Dose
Group II: Arm 3Experimental Treatment1 Intervention
XXB750 Medium Dose
Group III: Arm 2Experimental Treatment1 Intervention
XXB750 Low Dose
Group IV: Arm 5Active Control1 Intervention
Sacubitril/valsartan, open label tablet
Group V: Arm 1Placebo Group1 Intervention
Placebo Treatment

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,911 Previous Clinical Trials
4,250,541 Total Patients Enrolled
69 Trials studying Heart Failure
2,001,027 Patients Enrolled for Heart Failure
~68 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top